Seres Therapeutics, Inc. (MCRB) Receives Average Recommendation of “Buy” from Brokerages

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $19.00.

MCRB has been the subject of a number of research analyst reports. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Wednesday, July 5th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th.

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in Seres Therapeutics by 15.9% during the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Seres Therapeutics by 24.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 8,851 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Seres Therapeutics by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after purchasing an additional 9,060 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Seres Therapeutics by 74.8% in the 1st quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 8,841 shares during the last quarter. Finally, Highbridge Capital Management LLC raised its position in shares of Seres Therapeutics by 104.0% in the 1st quarter. Highbridge Capital Management LLC now owns 30,843 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 15,726 shares during the last quarter. 74.76% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://sportsperspectives.com/2017/09/12/seres-therapeutics-inc-mcrb-receives-average-recommendation-of-buy-from-brokerages.html.

Seres Therapeutics (NASDAQ:MCRB) opened at 14.80 on Tuesday. The firm’s market cap is $599.58 million. Seres Therapeutics has a 52-week low of $8.85 and a 52-week high of $15.09. The company’s 50 day moving average is $13.62 and its 200-day moving average is $11.21.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.10. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business had revenue of $3 million during the quarter, compared to analysts’ expectations of $3 million. During the same period in the previous year, the business earned ($0.70) EPS. The business’s revenue was up .0% compared to the same quarter last year. On average, equities analysts predict that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply